Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,582
datasets available to search
ShareScore release 0.9.0
Dataset results
7,582 results for “clinical study”
"COVID toes": a meta-analysis of case and observational studies on clinical, histopathological and laboratory findings.
<p><strong>Background: </strong>Coronavirus disease (COVID-19) is related to several extrapulmonary disorders; however, little is known about the clinical, laboratory and histopathological characteristics of pernio-like skin lesions associated with COVID-19 infection. <strong>Objective: </strong>To evaluate and summarize the clinical, laboratory and histopathological characteristics of pernio-like lesions reported in the literature. <strong>Methods: </strong>We conducted a search of the PubMed, SciELO and ScienceDirect databases for articles published between 1 January 2020 and 30 November 2020, following the PRISMA recommendations (PROSPERO registration ID: CRD42020225055). The target population was individuals with suspected or laboratory-confirmed COVID-19 with pernio-like lesions. Observational studies, research letters and case/series reports were all eligible for inclusion. Observational studies were evaluated using a random-effects model to calculate the weighted mean prevalence, overall mean and 95% confidence interval. We evaluated case studies using the chi-square test for dichotomous variables and the Mann-Whitney test for continuous variables. <strong>Results:</strong> A total of 187 patients from case reports and 715 patients from 18 observational studies were included. The mean age of patients was 16.6 (14.5–18.8) years. Feet were affected in 91.4% (87.0–94.4%) of patients in observational studies. The proportion of patients with a positive RT-PCR test was less than 15%. Lesion topography and morphology were associated with age. <strong>Conclusion:</strong> Lesions mostly occurred in pediatric patients, and the morphological characteristics tended to differ between pediatric and non-pediatric populations. There is a possible multifactorial component in lesion pathophysiology. The non-positivity of laboratory tests does not exclude an association with COVID-19. Chilblain-like lesions may be a late manifestation of COVID-19.</p>
Breaking the ice to improve motor outcomes in patients with chronic stroke: a retrospective clinical study on neuromodulation plus robotics
<p>Stroke is one of the main causes of impairment affecting daily activities and quality of life. There is a growing effort to potentiate the recovery of functional gait and to enable stroke patients to walk independently. To estimate the effects of dual-site transcranial direct current stimulation (dstDCS) on gait recovery in chronic stroke patients provided with robot-aided gait training (RAGT). Thirty-seven patients were included in this retrospective clinical study. Nine patients were provided with dstDCS during the first 10 min of RAGT by using Lokomat®Pro (on-RAGT), 15 patients immediately after RAGT (post-RAGT), and 13 patients immediately before RAGT (pre-RAGT). Each group improved over time concerning disability burden and lower limb strength. on-RAGT and post-RAGT experienced better improvement in balance (p < 0.001) and, moderately, gait endurance (p = 0.04) as compared to pre-RAGT. Furthermore, all treatments decreased the facilitation of the unaffected hemisphere (p < 0.001) and the inhibition of the affected hemisphere (p < 0.001). The duration of such aftereffects was found to be greater for post-RAGT. This is the first trial with dstDCS coupled with RAGT in chronic stroke patients with gait impairment. When timely coupled with RAGT, dstDCS may be considered an effective tool for the recovery of lower limb function in patients with first unilateral stroke in the chronic phase. Moreover, our data suggest the ductility of dstDCS concerning RAGT timing, thus making this intervention suitable in a neurorehabilitation setting and well adaptable to patients’ needs. </p>
Data from: Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson's disease: A retrospective study
<p><span>Patients with Parkinson's disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD.</span></p> <p><span>CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics.</span></p> <p><span>We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics.</span></p> <p><span>This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD.</span><span> Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.</span></p>
Supplemental material for the paper "Genotype-phenotype correlation, clinical presentation, and feminizing surgery in children with congenital adrenal hyperplasia - a nationwide study"
<p>This dataset provides documentation for the translation between historical nomenclature for variants in the CYP21A2 gene to the Human genome variation society nomenclature. </p> <p>Furthermore, it provides data on all Danish CYP21A2 variants included in the study and the translation into genotype groups: Null, A, B, C, and D. </p>
Dataset for a study:Clinical characteristics of SARS-CoV-2 delta variant infection in Xiamen
<p>This retrospective study aims to identify the clinical and demographic features of patients infected with the SARS-CoV-2 delta variant at a single institution in Xiamen, China.</p>
Clinical expression of programmed maxillary buccal expansion and buccolingual crown inclination with Invisalign® EX30® and SmartTrack® aligners and investigating the effect of 1-week vs 2-week aligner change regimes: A retrospective study.
<p><strong><em>Objective:</em></strong> The objective of this retrospective cohort study is to assess and compare the accuracy of three different Invisalign<sup>® </sup>treatment regimens involving variations of aligner change frequency and type of aligner material in achieving maxillary dental buccal expansion.</p> <p> </p> <p><strong><em>Methods:</em></strong> 120 adult patients whose treatment involved maxillary dental expansion with Invisalign<sup>®</sup> were selected. Three groups, each of 40 patients were identified: SmartTrack<sup>®</sup> one-week changes (ST1), SmartTrack<sup>®</sup> two-week changes (ST2) and EX30<sup>®</sup> two-week changes (EX2). The groups were assessed by comparing actual changes achieved with those prescribed by ClinCheck<sup>®</sup>. The rates of clinically significant inaccuracies (CSI) seen for buccal expansion (≥ 0.5mm) and buccolingual inclination (≥2°) during expansion were then ascertained.</p> <p> </p> <p><strong><em>Results:</em></strong> With respect to expansion, the ST1 group showed the highest rate of CSI at all tooth levels studied while the ST2 group showed the lowest rate of CSI as well as the lowest mean inaccuracy for each tooth level studied. In terms of buccolingual inclination, the ST1 group displayed the highest rate of CSI across all tooth levels studied, while the EX2 group displayed the lowest rate of CSI at all tooth levels except for the canine level where the ST2 group displayed the lowest rate of CSI. A tendency toward overexpression of buccal crown inclination, and underexpression of buccal expansion was seen at all tooth levels.</p> <p> </p> <p><strong><em>Conclusions:</em></strong> Two-week aligner change regimens offer improved accuracy compared with one-week aligner changes. SmartTrack<sup>®</sup> two-week changes were the most accurate for buccal expansion, while EX30<sup>®</sup> 2-week changes were the most accurate for buccolingual inclination.</p>
How much do pre-clinical medical students utilise the internet to study physiology?
<p>Tabulated data in Excel files which also includes statistical comparisons between and within GEM and DEM groups.</p>
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
ClinicalTrials.gov study NCT01116427. IPD Sharing: YES. Countries: 2. Publications: 2.
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
ClinicalTrials.gov study NCT00791492. IPD Sharing: Not stated. Countries: 6. Publications: 5.
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
ClinicalTrials.gov study NCT01144026. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
ClinicalTrials.gov study NCT01521559. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
ClinicalTrials.gov study NCT01356628. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide T
ClinicalTrials.gov study NCT02982187. IPD Sharing: NO. Countries: 2. Publications: 1.
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
ClinicalTrials.gov study NCT03404115. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Self or Clinic Administration of DepoProvera
ClinicalTrials.gov study NCT01019369. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
ClinicalTrials.gov study NCT01576523. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
ClinicalTrials.gov study NCT01761292. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
ClinicalTrials.gov study NCT00523978. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
ClinicalTrials.gov study NCT00630747. IPD Sharing: Not stated. Countries: 10. Publications: 4.
LINX Reflux Management System Clinical Study Protocol
ClinicalTrials.gov study NCT00776997. IPD Sharing: Not stated. Countries: 2. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.